参芪扶正注射液对血液恶性肿瘤化疗患者造血功能和免疫功能的影响

目的 研究参芪扶正注射液对血液系统恶性肿瘤化疗患者造血功能和免疫功能的影响。 方法80例均处于初治诱导缓解治疗阶段的血液肿瘤患者，分为治疗组和对照组，治疗组在化疗的同时给予参芪扶正注射液250 mL/（g·d） ，共14天，对照组单用化疗，两组其他支持治疗相同。观察两组化疗后缓解率，化疗前后血常规、T淋巴细胞亚群（CD+3、CD+4、CD+4/CD+8）和B淋巴细胞（CD－3CD+19）的水平。 结果 化疗后缓解率治疗组［90.0%(36/40)］与对照组［82.5%(33/40)］比较，差异无统计学意义（P>0.05）；化疗后治疗组外周血白细胞计数和血红蛋白均高于对照组（P＜0.05）；CD+3、CD+4及CD+4/CD+8水平均明显高于对照组（P＜0.05），CD－3CD+19 两组比较差异无统计学意义。 结论 参芪扶正注射液能减轻化疗对血液肿瘤患者骨髓造血功能的抑制，并能促进化疗患者骨髓造血功能的恢复；提高化疗患者的细胞免疫功能；改善血液肿瘤化疗患者的生活质量。

Effect of Shenqi Fuzheng Injection for Hemopoietic and Immune Function Reconstruction in Patients with Hematologic Malignancies Undergoing Chemotherapy

Objective To investigate the effect of Shenqi Fuzheng Injection (SFI) for hemopoietic and immune function reconstruction in patients with hematologic malignancies (HM) after chemotherapy. Methods Eighty HM patients at remission inducing stage of initial treatment were randomly assigned to two groups, the treatment group treated with SFI (250 mL daily) plus chemotherapy and the control group only treated with chemotherapy for 14 days, with same supportive treatments administered to both. Levels of blood rout...